HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

gardiquimod

Networked: 16 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - gardiquimod: 16
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Aminoquinolines: 29
        gardiquimod: 16

Experts

1.	Bennet, Laura: 3 articles (06/2021 - 01/2019)
2.	Cho, Kenta H T: 3 articles (06/2021 - 01/2019)
3.	Fraser, Mhoyra: 3 articles (06/2021 - 01/2019)
4.	Gunn, Alistair J: 3 articles (06/2021 - 01/2019)
5.	Dean, Justin M: 2 articles (06/2021 - 01/2020)
6.	Xu, Bing: 2 articles (06/2021 - 01/2019)
7.	Davidson, Joanne O: 2 articles (01/2020 - 01/2019)
8.	Wassink, Guido: 2 articles (01/2020 - 01/2019)
9.	Cheng, Feng-Wei: 2 articles (02/2016 - 10/2015)
10.	Geng, Xiaoping: 2 articles (02/2016 - 10/2015)

Related Diseases

1.	Neoplasms (Cancer) 09/23/2020 - "Here, we report a multifunctional near-infrared (NIR)-responsive core-shell nanoparticle, which enables (i) photothermal ablation of cancer cells for generating tumor-associated antigen (TAA) and (ii) triggered release of an immunomodulatory drug (gardiquimod) for starting a series of immunological events. " 01/01/2017 - "This article reviewed the anti-tumor activity and mechanism of TLR7 agonists that are frequently applied in preclinical and clinical investigations, and mainly focused on small synthetic molecules, including imiquimod, resiquimod, gardiquimod, and 852A, etc." 02/01/2016 - "The present study aimed to investigate the effects of the TLR7 agonist, gardiquimod, on ERK1/2 signaling pathway, and on the expression of genes involved in the pathogenesis of cancer, including phosphatase and tensin homolog deleted on chromosome 10 (PTEN), p53, type Ⅲ interferon (IFN-λ1), vascular endothelial growth factor (VEGF), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1). "
2.	Sepsis (Septicemia) 08/01/2017 - "In this study, we evaluated the potential role of TLR7 agonist gardiquimod (GDQ) in oxidative stress (OS) in liver injury induced by sepsis. " 08/01/2017 - "Intraperitoneal gardiquimod protects against hepatotoxicity through inhibition of oxidative stress and inflammation in mice with sepsis."
3.	Inflammation (Inflammations) 08/01/2017 - "Intraperitoneal gardiquimod protects against hepatotoxicity through inhibition of oxidative stress and inflammation in mice with sepsis." 01/01/2021 - "VRG have demonstrated equal or similar responses to RNA (SAV, IPNV, PRV, and ISAV), and DNA (gill pox) viruses, injection of bacterial DNA (plasmid) and exposure of cells to PAMP (CpG and gardiquimod) and relatively low sensitivity to inflammation and bacteria. "
4.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 05/01/2012 - "C57Bl/6, TNF(-/-), interferon (IFN) regulatory factor 7(-/-), or type I IFN receptor (IFNAR)(-/-) mice were subcutaneously administered the TLR7 agonist Gardiquimod (GDQ) 72 hours before middle cerebral artery occlusion. "
5.	Pancreatic Neoplasms (Pancreatic Cancer) 02/01/2016 - "These findings indicated that the effect of TLR7 agonists, including gardiquimod, on gene expression in BxPC-3 pancreatic cancer cells was partly associated with the mitogen-activated protein kinase-ERK1/2 signaling pathway."

Related Drugs and Biologics

1.	Interferons
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Matrix Metalloproteinase 9 (Gelatinase B)
4.	Tissue Inhibitor of Metalloproteinase-1
5.	Phosphoric Monoester Hydrolases (Phosphatases)
6.	Tensins
7.	Imiquimod (Aldara)
8.	Cyclin B1
9.	Leishmaniasis Vaccines
10.	Toll-Like Receptors (Toll-Like Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy